文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

调节性细胞治疗在自身免疫性疾病中的新作用。

The emerging role of regulatory cell-based therapy in autoimmune disease.

机构信息

Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Universal Scientific Education and Research Network (USERN) Office, Kermanshah University of Medical Sciences, Kermanshah, Iran.

出版信息

Front Immunol. 2022 Dec 14;13:1075813. doi: 10.3389/fimmu.2022.1075813. eCollection 2022.


DOI:10.3389/fimmu.2022.1075813
PMID:36591309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9795194/
Abstract

Autoimmune disease, caused by unwanted immune responses to self-antigens, affects millions of people each year and poses a great social and economic burden to individuals and communities. In the course of autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes mellitus, and multiple sclerosis, disturbances in the balance between the immune response against harmful agents and tolerance towards self-antigens lead to an immune response against self-tissues. In recent years, various regulatory immune cells have been identified. Disruptions in the quality, quantity, and function of these cells have been implicated in autoimmune disease development. Therefore, targeting or engineering these cells is a promising therapeutic for different autoimmune diseases. Regulatory T cells, regulatory B cells, regulatory dendritic cells, myeloid suppressor cells, and some subsets of innate lymphoid cells are arising as important players among this class of cells. Here, we review the roles of each suppressive cell type in the immune system during homeostasis and in the development of autoimmunity. Moreover, we discuss the current and future therapeutic potential of each one of these cell types for autoimmune diseases.

摘要

自身免疫性疾病是由针对自身抗原的异常免疫反应引起的,每年影响数百万人,给个人和社区带来了巨大的社会和经济负担。在包括类风湿性关节炎、系统性红斑狼疮、1 型糖尿病和多发性硬化症在内的自身免疫性疾病中,针对有害抗原的免疫反应与针对自身抗原的耐受性之间的平衡被打破,导致针对自身组织的免疫反应。近年来,已经鉴定出各种调节性免疫细胞。这些细胞的质量、数量和功能的紊乱与自身免疫性疾病的发展有关。因此,针对这些细胞进行靶向或工程改造是治疗不同自身免疫性疾病的一种有前途的方法。调节性 T 细胞、调节性 B 细胞、调节性树突状细胞、髓源性抑制细胞和一些先天淋巴细胞亚群在这类细胞中作为重要的参与者出现。在这里,我们回顾了每种抑制性细胞类型在免疫系统中的稳态和自身免疫发展中的作用。此外,我们还讨论了这些细胞类型中的每一种用于治疗自身免疫性疾病的当前和未来的治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/9795194/336aa26e0133/fimmu-13-1075813-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/9795194/5a94c152261b/fimmu-13-1075813-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/9795194/108bc825ad76/fimmu-13-1075813-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/9795194/336aa26e0133/fimmu-13-1075813-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/9795194/5a94c152261b/fimmu-13-1075813-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/9795194/108bc825ad76/fimmu-13-1075813-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/9795194/336aa26e0133/fimmu-13-1075813-g003.jpg

相似文献

[1]
The emerging role of regulatory cell-based therapy in autoimmune disease.

Front Immunol. 2022

[2]
The extra-islet pancreas supports autoimmunity in human type 1 diabetes.

Elife. 2025-4-15

[3]
Response to self antigen imprints regulatory memory in tissues.

Nature. 2011-11-27

[4]
Autoimmune Lymphoproliferative Syndrome

1993

[5]
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.

Curr Neurol Neurosci Rep. 2025-7-1

[6]
The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull. 2024-7-8

[7]
The roles of transient receptor potential vanilloid in autoimmune diseases.

Autoimmun Rev. 2025-7-8

[8]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[9]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[10]
Incidence, stage and outcome of malignant melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks?

Br J Dermatol. 2025-6-20

引用本文的文献

[1]
Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients.

Front Immunol. 2025-8-15

[2]
Interactions between the gut microbiota and immune cell dynamics: novel insights into the gut-bone axis.

Gut Microbes. 2025-12

[3]
Strategies and delivery systems for cell-based therapy in autoimmunity.

Front Drug Deliv. 2024-8-8

[4]
Tumor-educated cells in tumor microenvironment: Key drivers of immunotherapy resistance.

Chin J Cancer Res. 2025-6-30

[5]
Recent advances in regulatory immune cells: exploring the world beyond Tregs.

Front Immunol. 2025-5-16

[6]
"Remodeling the intestinal immune microenvironment": immune regulation and tissue regeneration by mesenchymal stem/stromal cells in the repair microenvironment of inflammatory bowel disease.

Front Immunol. 2025-5-13

[7]
Global, regional and national disparities and temporal trends of common autoimmune disease burdens among children and adolescents from 1990 to 2019.

BMJ Glob Health. 2025-4-3

[8]
Conversion of T Effector Cells Into T Regulatory Cells in Type 1 Diabetes/Latent Autoimmune Diabetes of Adults by Inhibiting eIF5A and Notch Pathways.

Immunotargets Ther. 2025-3-13

[9]
Expanding the engineered Treg multiverse.

Mol Ther. 2025-3-5

[10]
Human immune system: Exploring diversity across individuals and populations.

Heliyon. 2025-1-13

本文引用的文献

[1]
Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases.

Stem Cell Res Ther. 2022-3-7

[2]
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus.

Expert Opin Biol Ther. 2022-4

[3]
IL-6 and TNFα Drive Extensive Proliferation of Human Tregs Without Compromising Their Lineage Stability or Function.

Front Immunol. 2021

[4]
Modeling human T1D-associated autoimmune processes.

Mol Metab. 2022-2

[5]
CAR Treg: A new approach in the treatment of autoimmune diseases.

Int Immunopharmacol. 2022-1

[6]
Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients.

Sci Transl Med. 2021-10-27

[7]
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.

Front Immunol. 2021

[8]
Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases.

Autoimmun Rev. 2022-1

[9]
Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity.

Cell Rep. 2021-8-3

[10]
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.

JCI Insight. 2021-9-22

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索